Global Intragastric Balloon Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Intragastric Balloon Market Size

• the global intragastric balloon market size was valued at USD 132.76 million in 2025and is expected to reach USD 307.05 million by 2033, at a CAGR of 11.05% during the forecast period
• The market growth is primarily driven by the rising prevalence of obesity and related metabolic disorders, along with increasing preference for minimally invasive, non-surgical weight management procedures across global healthcare systems
• Furthermore, growing awareness regarding obesity treatment alternatives, expanding access to bariatric care, and technological advancements in endoscopic balloon systems are strengthening clinical adoption. These converging factors are accelerating the uptake of intragastric balloon solutions, thereby significantly boosting the industry's growth

Intragastric Balloon Market Analysis

• Intragastric balloons, minimally invasive endoscopic devices placed temporarily in the stomach to promote satiety and support weight loss, are increasingly important in modern obesity management across clinical and outpatient settings due to their non-surgical nature, reversibility, and suitability for patients who are not candidates for bariatric surgery
• The escalating demand for intragastric balloons is primarily driven by the rising global prevalence of obesity and metabolic disorders, increasing preference for minimally invasive weight-loss procedures, and growing awareness of endoscopic bariatric treatment options among patients and healthcare providers
• North America dominated the intragastric balloon market with the largest revenue share of 38.5% in 2025, supported by high obesity rates, advanced healthcare infrastructure, and strong adoption of endoscopic weight-loss procedures, with the U.S. leading growth through expanding bariatric clinics and increasing utilization of non-surgical obesity interventions
• Asia-Pacific is expected to be the fastest growing region in the intragastric balloon market during the forecast period due to rising obesity incidence, rapid urbanization, increasing healthcare expenditure, and expanding awareness of minimally invasive obesity treatment options in emerging economies
• The single segment dominated the market with a market share of 61.7% in 2025, driven by its widespread clinical acceptance, procedural simplicity, and predictable safety and efficacy profile in short-term weight reduction management

Report Scope and Intragastric Balloon Market Segmentation

Intragastric Balloon Market Trends

“Rising Shift Toward Minimally Invasive and Digitally Assisted Obesity Treatment”

• A significant and accelerating trend in the global intragastric balloon market is the growing preference for minimally invasive, endoscopic weight-loss procedures supported by digital monitoring and connected healthcare platforms, improving patient compliance and clinical outcomes
• For instance, Allurion Balloon integrates with mobile health applications that allow patients to track weight loss progress and receive remote clinical support during treatment
• Integration of digital health tools and remote patient monitoring is enhancing post-procedure management by enabling physicians to track dietary habits, weight trends, and complications in real time, improving treatment success rates
• The increasing use of swallowable and non-surgical balloon systems is simplifying obesity treatment pathways and expanding access to patients who are unwilling or unfit for bariatric surgery
• The growing adoption of combination therapy approaches, where intragastric balloons are paired with pharmacological weight-loss treatments such as GLP-1 agonists, is improving overall patient outcomes and long-term weight management success
• Rising focus on personalized obesity care pathways is enabling clinicians to better match balloon type and treatment duration with individual patient profiles, improving safety and effectiveness
• This trend towards safer, outpatient-based, and digitally supported weight management is fundamentally reshaping patient expectations in obesity care, driving demand for more convenient therapeutic solutions
• The demand for intragastric balloon solutions with improved safety profiles, shorter procedure time, and integrated digital follow-up is growing rapidly across both developed and emerging healthcare markets

Intragastric Balloon Market Dynamics

Driver

“Rising Obesity Prevalence and Demand for Non-Surgical Weight Loss Solution”

• The increasing global prevalence of obesity and metabolic disorders, coupled with rising awareness of non-surgical weight-loss alternatives, is a major driver for the growing demand for intragastric balloon procedures
• For instance, in May 2025, Apollo Endosurgery expanded its endoscopic bariatric portfolio to address rising demand for minimally invasive obesity treatments across hospitals and specialty clinics
• Patients are increasingly opting for intragastric balloons as they provide a reversible and lower-risk alternative to bariatric surgery while still delivering clinically significant weight reduction outcomes
• Furthermore, growing healthcare investments in obesity management programs and the expansion of bariatric care centers are accelerating adoption of endoscopic weight-loss solutions
• The convenience of outpatient procedures, reduced hospitalization time, and improved safety profile are key factors propelling the uptake of intragastric balloon therapies across global healthcare systems
• Rising physician preference for endoscopic interventions over invasive surgical procedures is further accelerating clinical adoption, particularly in high-risk obese patient populations

Restraint/Challenge

“Procedure-Related Side Effects and Limited Long-Term Effectiveness Concerns”

• Concerns related to gastrointestinal side effects such as nausea, vomiting, and abdominal discomfort, along with the temporary nature of weight loss outcomes, pose a significant challenge to wider market adoption
• For instance, clinical reports associated with Orbera balloon procedures have highlighted cases of intolerance leading to early device removal in some patients
• The requirement for device removal after a limited duration and potential weight regain after deflation reduces long-term patient confidence in intragastric balloon therapy
• In addition, variability in patient response and the need for strict dietary adherence during treatment can limit overall effectiveness in real-world settings
• Limited reimbursement coverage in several regions further restricts patient access, particularly in cost-sensitive healthcare systems
• On the other hand, lack of reimbursement for such procedures in most countries can potentially restrain the market demand and obstruct the market's growth rate. The market for intragastric balloons will face difficulties due to a shortage of qualified workers and inadequate healthcare infrastructure in underdeveloped nations
• Overcoming these challenges through improved balloon design, better patient selection criteria, enhanced post-procedure support programs, and expanded insurance coverage will be vital for sustained market growth

Intragastric Balloon Market Scope

The market is segmented on the basis of type, filling material, and end use.

• By Type

On the basis of type, the intragastric balloon market is segmented into single intragastric balloons, dual intragastric balloons, and triple intragastric balloons. The single intragastric balloon segment dominated the market with the largest revenue share of 61.7% in 2025, driven by its widespread clinical adoption, established safety profile, and predictable weight-loss outcomes in standard obesity treatment cases. Physicians prefer single balloon systems due to their ease of placement, lower complication risk, and shorter procedural time compared to multi-balloon configurations. In addition, single balloons are more widely approved and available across major healthcare markets, supporting their strong utilization in hospitals and bariatric clinics. Their compatibility with outpatient procedures and strong patient acceptance further strengthens dominance. Growing awareness and reimbursement support in developed regions continue to reinforce demand for single balloon systems.

The dual intragastric balloon segment is expected to witness the fastest growth rate of 18.9% from 2026 to 2033, driven by improved efficacy in achieving greater gastric volume occupancy and enhanced weight-loss outcomes compared to single balloon systems. Dual balloons provide better stomach filling balance, reducing migration risk and improving patient tolerance in selected cases. Increasing clinical preference for more effective short-term obesity interventions is accelerating adoption in specialty obesity centers. Furthermore, advancements in balloon material technology are improving safety and reducing complication rates. Rising demand for optimized weight-loss results in patients with higher BMI is also contributing to growth. Expanding availability in emerging healthcare markets further supports rapid segment expansion.

• By Filling Material

On the basis of filling material, the intragastric balloon market is segmented into saline-filled and gas-filled balloons. The saline-filled segment dominated the market with the largest revenue share of 74.3% in 2025, driven by its proven clinical safety, long-standing usage history, and ability to provide effective gastric volume expansion. Saline-filled balloons are widely preferred due to their adjustable volume capacity and lower risk profile in case of leakage, as saline is safely absorbed by the body. They also offer better durability and stability within the stomach compared to gas-based alternatives. Strong physician familiarity and regulatory approvals across key regions further support dominance. In addition, higher weight-loss predictability and consistent clinical outcomes make saline-filled systems the preferred standard of care.

The gas-filled segment is expected to witness the fastest growth rate of 21.4% from 2026 to 2033, driven by its lightweight structure, improved patient comfort, and reduced gastrointestinal side effects such as pressure and cramping. Gas-filled balloons are easier to swallow in newer capsule-based designs, increasing patient acceptance. Their minimally invasive insertion process is attracting demand in outpatient obesity treatment settings. Growing innovation in biodegradable and swallowable balloon systems is further accelerating adoption. Rising preference for less intrusive weight-loss solutions among younger and first-time obesity patients is also boosting growth. Expanding clinical trials and product approvals are expected to further support market penetration.

• By End Use

On the basis of end use, the intragastric balloon market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment dominated the market with the largest revenue share of 52.6% in 2025, driven by the availability of advanced endoscopic infrastructure, skilled gastroenterologists, and strong procedural safety protocols. Hospitals are the primary centers for balloon insertion and removal procedures due to their ability to manage complications and provide comprehensive obesity care. High patient inflow for bariatric and gastrointestinal treatments further supports dominance. In addition, favorable reimbursement frameworks in many developed markets encourage hospital-based procedures. Hospitals also benefit from multidisciplinary obesity management teams, enhancing treatment outcomes and patient trust.

The ambulatory surgical centers (ASCs) segment is expected to witness the fastest growth rate of 20.8% from 2026 to 2033, driven by the increasing shift toward outpatient and same-day obesity procedures. ASCs offer lower treatment costs, reduced hospital stay, and faster patient turnaround compared to traditional hospital settings. Rising preference for minimally invasive procedures that do not require prolonged monitoring is supporting adoption in ASCs. Technological advancements in safer balloon systems are making outpatient procedures more feasible. Expanding ASC infrastructure in emerging economies is further boosting access. Growing demand for cost-effective weight-loss interventions is accelerating the shift toward ASC-based treatment delivery.

Intragastric Balloon Market Regional Analysis

• North America dominated the intragastric balloon market with the largest revenue share of 38.5% in 2025, supported by high obesity rates, advanced healthcare infrastructure, and strong adoption of endoscopic weight-loss procedures
• Patients and healthcare providers in the region highly prefer intragastric balloon therapies due to their non-surgical nature, shorter recovery time, and effectiveness as an alternative to traditional bariatric surgery
• This widespread adoption is further supported by advanced healthcare infrastructure, strong presence of specialized obesity treatment centers, and high awareness of weight management solutions, establishing intragastric balloons as a preferred intervention in clinical obesity care

U.S. Intragastric Balloon Market Insight

The U.S. intragastric balloon market captured the largest revenue share within North America in 2025, driven by rapidly increasing obesity prevalence and strong uptake of endoscopic weight-loss procedures in both hospital and specialty clinic settings. Patients in the country are increasingly opting for non-surgical and reversible obesity treatments due to shorter recovery times and lower complication risks compared to bariatric surgery. The market is further supported by advanced healthcare infrastructure, high healthcare spending, and strong presence of leading medical device companies offering innovative balloon systems. Growing integration of obesity management programs with digital health monitoring and post-procedure support is further accelerating adoption across the U.S. In addition, rising physician preference for minimally invasive interventions in high-BMI patients is strengthening procedural volumes.

Europe Intragastric Balloon Market Insight

The Europe intragastric balloon market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising obesity rates and increasing preference for non-surgical weight management solutions. The region benefits from strong regulatory support for minimally invasive medical devices and growing healthcare initiatives focused on obesity prevention and treatment. European patients are increasingly adopting intragastric balloons due to their safety profile, effectiveness, and integration into structured weight management programs across hospitals and clinics. Expansion of public health campaigns targeting obesity reduction and lifestyle diseases is also supporting greater awareness and adoption of endoscopic bariatric solutions.

U.K. Intragastric Balloon Market Insight

The U.K. intragastric balloon market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing obesity prevalence and rising demand for outpatient bariatric procedures. Growing awareness of endoscopic weight-loss solutions is encouraging both public and private healthcare providers to expand access to balloon-based treatments. The country’s strong private healthcare sector and increasing focus on preventive healthcare are further supporting market expansion. In addition, rising demand for minimally invasive alternatives to surgical bariatric procedures is contributing to increased clinical adoption across urban healthcare facilities.

Germany Intragastric Balloon Market Insight

The Germany intragastric balloon market is expected to expand at a considerable CAGR during the forecast period, fueled by high obesity burden and strong demand for technologically advanced obesity treatment solutions. Germany’s well-developed healthcare infrastructure and emphasis on minimally invasive procedures are promoting adoption of endoscopic weight-loss therapies. Increasing integration of intragastric balloons into multidisciplinary obesity management programs is further supporting steady market growth. Growing patient preference for safer, reversible treatment options is also strengthening demand across both hospital and specialty care settings.

Asia-Pacific Intragastric Balloon Market Insight

The Asia-Pacific intragastric balloon market is poised to grow at the fastest CAGR of 22% during 2026 to 2033, driven by rising obesity rates, urbanization, and increasing healthcare expenditure across emerging economies. Growing awareness of non-surgical weight-loss procedures and expanding access to bariatric care are accelerating adoption of intragastric balloon treatments in the region. In addition, increasing availability of cost-effective devices and expansion of specialty clinics are making treatment more accessible to a broader patient population. Rapid lifestyle changes and dietary shifts are further contributing to rising obesity cases, supporting long-term market expansion.

Japan Intragastric Balloon Market Insight

The Japan intragastric balloon market is gaining momentum due to advanced healthcare infrastructure, aging population, and rising focus on lifestyle-related disease management. The country’s preference for minimally invasive and high-safety medical procedures is supporting adoption of endoscopic obesity treatments. Integration of digital health monitoring and structured weight management programs is further enhancing treatment outcomes and market penetration. Increasing focus on preventive healthcare and early intervention for obesity-related conditions is also supporting steady demand growth.

India Intragastric Balloon Market Insight

The India intragastric balloon market accounted for the largest revenue share in Asia-Pacific in 2025, driven by rapid urbanization, rising obesity prevalence, and expanding middle-class population. Increasing awareness of obesity-related health risks and growing acceptance of non-surgical weight-loss treatments are supporting market growth across urban centers. The availability of affordable treatment options, expansion of bariatric clinics, and government focus on healthcare infrastructure development are key factors propelling market expansion. Rising penetration of private healthcare providers and increasing medical tourism for obesity treatment are further strengthening market growth dynamics.

Intragastric Balloon Market Share

The Intragastric Balloon industry is primarily led by well-established companies, including:

• Apollo Endosurgery, Inc. (U.S.)
• Allurion Technologies, Inc. (U.S.)
• ReShape Lifesciences, Inc. (U.S.)
• Spatz FGIA, LLC (U.S.)
• Lexel Medical (France)
• MEDSIL Ltd. (Russia)
• Cousin Biotech (France)
• Districlass Médical (France)
• Helioscopie S.A.S. (France)
• Endalis S.A. (France)
• Silimed Indústria de Implantes Ltda (Brazil)
• NATRA (India)
• Bariatric Solutions Pty Ltd (Australia)
• Heliosphere Balloon Systems (France)
• EndoGastric Solutions, Inc. (U.S.)
• GI Dynamics, Inc. (U.S.)
• MedSil Medical Devices (Russia)
• Spatz Medical (U.S.)
• Allurion Medical Technologies UK Ltd (U.K.)
• Obalon Therapeutics, Inc. (U.S.)

What are the Recent Developments in Global Intragastric Balloon Market?

• In February 2025, Allurion Technologies advanced its next-generation intragastric balloon system (Allurion Balloon platform) with continued global commercialization and regulatory progress in key markets, including expanded clinical adoption in Europe and emerging regions. The system is designed as a swallowable, non-endoscopic gastric balloon aimed at simplifying obesity treatment and improving patient access to minimally invasive weight-loss procedures. It integrates a digital health ecosystem that enables remote patient monitoring, weight tracking, and physician-guided behavioral support. This development highlights the growing shift toward outpatient-based bariatric care and device-led obesity management.
• In June 2024, Allurion Technologies expanded the clinical and commercial footprint of its gastric balloon program across multiple international markets, strengthening adoption of its swallowable intragastric balloon system. The solution is positioned as a minimally invasive alternative to bariatric surgery, requiring no endoscopy for placement or removal in many cases. It is supported by mobile-based monitoring tools that help physicians track patient progress and improve long-term outcomes. The expansion reflects rising preference for outpatient obesity treatments and technology-enabled weight management solutions
• In May 2023, the U.S. FDA continued evaluation and clinical oversight activities for intragastric balloon systems such as Orbera and other endoscopic bariatric devices used in obesity management. These systems are designed to temporarily occupy stomach volume to induce satiety and support weight reduction in obese patients. The regulatory pathway has supported controlled clinical adoption of minimally invasive weight-loss devices in specialized centers. This reflects increasing emphasis on non-surgical obesity treatment alternatives in the U.S. healthcare system
• In August 2022, Apollo Endosurgery continued global clinical utilization of its Orbera intragastric balloon system, one of the most widely used saline-filled gastric balloons for obesity treatment. The device is placed endoscopically and removed after a defined treatment period to support significant short-term weight loss. It is widely adopted in bariatric clinics due to its established safety profile and predictable clinical outcomes. This development reflects strong ongoing demand for saline-filled single-balloon systems in global obesity management
• In March 2021, early adoption and clinical expansion of intragastric balloon therapies continued across Europe and Asia-Pacific, driven by increasing obesity prevalence and rising acceptance of endoscopic bariatric solutions. Devices such as Orbera and similar saline-filled balloons were increasingly integrated into structured weight management programs in hospitals and specialty clinics. The technology gained traction as a reversible alternative to surgical bariatric procedures

SKU-54407